Positive impactCompany

Divi's Laboratories Q2 Review: Goldman Sachs, Jefferies, JPMorgan Raise Target Prices; Kotak Maintains Sell

NDTV Profit 9 Nov·9 Nov 2026, 3:35 am

Divi's Laboratories reported a strong second quarter, prompting several global brokerage houses to revise their price targets. Goldman Sachs and Jefferies have raised their targets significantly, while JPMorgan has also increased its outlook. The positive sentiment is driven by the company's expanding Contract Development and Manufacturing Organization (CDMO) business and its growing capabilities in peptide manufacturing.

This move by major global investors signals confidence in the company's long-term growth trajectory. For retail investors, it highlights Divi's Laboratories' potential to capture more value from its expanding service portfolio. The stock is currently trading at a premium valuation, so investors should monitor the company's execution on its new projects and the overall demand in the global pharma market.

Affected stocks

Bullish1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Divi's Laboratories (DIVISLAB).
  • Category: Company.
  • AI reads the tone as positive (potentially bullish) for the stock.

Why it matters

A routine update for Divi's Laboratories. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at NDTV Profit.

More Company news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.